Isaiah Selkridge
Papers
2
Total Citations
145
H-Index
2
About
Isaiah Selkridge is a pioneering translational researcher at the forefront of personalized oncology, leveraging innovative model systems to match rare and difficult-to-treat cancers with effective therapies. His work centers on developing high-throughput, organism-based drug screening platforms to overcome the limitations of traditional genomics. Selkridge’s most impactful contribution is the creation of "hindgut," a personalized platform using Drosophila (fruit flies) to perform robotics-based drug screens. In a landmark 2019 study (107 citations), he used this system to identify the combination of trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer—a notoriously challenging target. The treatment produced a strong partial response, with target and nontarget lesions remaining stable for 11 months. He further demonstrated the platform’s versatility in a 2021 study (38 citations) by identifying a novel personalized therapy for adenoid cystic carcinoma, a rare salivary gland cancer with limited treatment options. By bridging the gap between bench and bedside, Selkridge’s work provides a powerful, actionable strategy for patients who have exhausted standard-of-care options, establishing him as a leader in functional precision medicine.
Research Focus
Key Achievements
Top Papers
- 1
- 2